Drug Discovery Partnership: Filling the Pipeline (DDP2009)

Venue: Hyatt Regency Boston

Location: Boston, Massachusetts, United States

Event Date/Time: Oct 28, 2009 End Date/Time: Oct 30, 2009
Registration Date: Oct 28, 2009
Early Registration Date: Aug 31, 2009
Report as Spam


Opal Events presents its next conference Drug Discovery Partnership: Filling the Pipeline at the Hyatt Regency in Boston October 28-30, 2009. This two-tracked event is designed specifically to discuss and debate new partnership models between Academia and Industry, and to solidify strategies in integrating early-stage drug discovery projects.

The event will kick off with pre-conference workshops on the first day, with main sessions on the following days to discuss the possibilities in academia-industrial partnerships and strategic alliances in addition to showcasing new opportunities for partnerships. Networking activities throughout the event will allow you to get in front of potential partners and provide you with opportunities to increase your positional strength in this volatile market.

Topics to be covered include:

Valuation and pricing for early-stage technologies
Licensing/ Patenting/ IP Issues
Funding for start-up
NIH Roadmap
Technical integration (target identification, assay development, screening, hit-to-lead)
Eli Lilly’s Phenotypic Drug Discovery (PD2) Initiative

Distinguished Speaker Faculty Includes:

Marcie Glicksman, Ph.D., Sr. Director Leads Discovery and Assistant Professor, Harvard NeuroDiscovery Center, Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School
Melvin Reichman, Ph.D., Director LIMR Chemical Genomics Center (LCGC), Lankenau Institute for Medical Research
Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute (NHGRI), National Institutes of Health
Shawnmarie Mayrand-Chung, Ph.D., J.D., Program Director for the Biomarkers Consortium, Program on Public-Private Partnerships, National Institutes of Health
Damian O’Connell, MD, Ph.D., VP, Clinical Research Head for the Indications Discovery Unit (IDU), Pfizer; Chairman, Board at Molecular Medicine Ireland
Robert Sarisky, Ph.D., MBA, VP, External Research and Early Development, Johnson & Johnson
Giora Feuerstein, M.D., Assistant Vice President, Head, Discovery Translational Medicine, Wyeth Research
Dr. Frederick Monsma, Director, New Lead Discovery, Schering-Plough Research Institute
Dr. Thomas Engler, Senior Research Advisor, Discovery Chemistry Research and Technologies, Lilly Research Laboratories, A Division of Eli Lilly & Co.
David Brener, Ph.D., Director, Research and Development Alliances, Pfizer Canada
Ken Duncan, Ph.D. (Invite), Senior Program Officer, Global Health Program, Bill & Melinda Gates Foundation
Dr. Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford
Jack Price, B.A, Ph.D., Professor of Developmental Neurobiology, Director, Centre for the Cellular Basis of Behavior, King’s College London
Dutch Chung, Ph.D., J.D., Senior Attorney, Wilson Sonsini Goodrich & Rosati
Gregory N. Tew, Assistant Professor, Polymer Science and Engineering, University of Massachusetts
Nicola Tolliday, Ph.D., Manager, Screening Outreach, Broad Institute
David Schultz, Ph.D., Wistar Scientist, Director, Protein Production, Libraries & Molecular Screening Facility, Wistar Institute
Adam Renslo, Ph.D., Associate Director, Chemistry, Adjunct Assistant Professor of Pharmaceutical Chemistry, University of California, San Francisco
Dr. Seth J. Goldenberg, Senior Scientist, Progenra, Inc.
Lars Knutsen, President, Discovery Pharma Consulting LLC
O. Prem Das, Ph.D., Business Development and Technology Transfer Consultant

Sponsorship and Exhibiting Opportunities

If you are interested in sponsorship, exhibiting or speaking opportunities, please contact Kay Ye at kye@opalevents.org or 212 532-9898, extension 263.

Register by August 31 and save $1,000 off the standard registration fee!


1 Avenue De Lafayette
United States